Smoking-related bias of standardized mortality ratios in rheumatoid arthritis: A modeling study

IF 4.6 2区 医学 Q1 RHEUMATOLOGY Seminars in arthritis and rheumatism Pub Date : 2024-11-17 DOI:10.1016/j.semarthrit.2024.152599
Michael M. Ward
{"title":"Smoking-related bias of standardized mortality ratios in rheumatoid arthritis: A modeling study","authors":"Michael M. Ward","doi":"10.1016/j.semarthrit.2024.152599","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Standardized mortality ratios (SMRs) for rheumatoid arthritis (RA) are age- and sex-matched to the general population, but may be biased because smoking is more common in the RA group. This modeling study used national mortality data on smokers and non-smokers to estimate the effect on SMRs of the higher smoking prevalences typically found in RA.</div></div><div><h3>Methods</h3><div>Data from the United States National Health Interview Surveys 1999–2004 were used to create hypothetical cohorts with an age-sex composition typical of patients with RA (age 30 to 79; 70 % women). The reference cohort had the smoking prevalence of the general population (21.8 % current smokers). Additional cohorts were created that had higher proportions of smokers, approximating the prevalence of smoking commonly present in RA, with smoking relative risks of 1.25, 1.5, 1.75, and 2.0 compared to the reference cohort. SMRs were computed on 2000 replicate samples in which mortality over 10 years and 15 years was compared between the higher-smoking simulated RA cohorts and the reference cohort.</div></div><div><h3>Results</h3><div>The reference cohort had a prevalence of current smoking of 21.8 %. In a hypothetical RA cohort with a higher smoking prevalence, equal to a smoking relative risk of 2.0 compared to the general population, the median SMR for RA was 1.23 at 10 years and 1.17 at 15 years. At a smoking prevalence equivalent to a relative risk of 1.25, the median SMR for RA was 1.07 at 10 years and 1.04 at 15 years. Results were similar for SMRs based on relative risks that compared ever smokers to never smokers. Differences in smoking intensity between the hypothetical RA groups and reference cohorts had small effects on SMRs.</div></div><div><h3>Conclusions</h3><div>SMRs in RA may be inflated by even small increases in the prevalence of smoking relative to the general population. In these cases, an SMR benchmark of 1.0 to represent equal mortality outcomes would be too strict.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152599"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017224002397","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Standardized mortality ratios (SMRs) for rheumatoid arthritis (RA) are age- and sex-matched to the general population, but may be biased because smoking is more common in the RA group. This modeling study used national mortality data on smokers and non-smokers to estimate the effect on SMRs of the higher smoking prevalences typically found in RA.

Methods

Data from the United States National Health Interview Surveys 1999–2004 were used to create hypothetical cohorts with an age-sex composition typical of patients with RA (age 30 to 79; 70 % women). The reference cohort had the smoking prevalence of the general population (21.8 % current smokers). Additional cohorts were created that had higher proportions of smokers, approximating the prevalence of smoking commonly present in RA, with smoking relative risks of 1.25, 1.5, 1.75, and 2.0 compared to the reference cohort. SMRs were computed on 2000 replicate samples in which mortality over 10 years and 15 years was compared between the higher-smoking simulated RA cohorts and the reference cohort.

Results

The reference cohort had a prevalence of current smoking of 21.8 %. In a hypothetical RA cohort with a higher smoking prevalence, equal to a smoking relative risk of 2.0 compared to the general population, the median SMR for RA was 1.23 at 10 years and 1.17 at 15 years. At a smoking prevalence equivalent to a relative risk of 1.25, the median SMR for RA was 1.07 at 10 years and 1.04 at 15 years. Results were similar for SMRs based on relative risks that compared ever smokers to never smokers. Differences in smoking intensity between the hypothetical RA groups and reference cohorts had small effects on SMRs.

Conclusions

SMRs in RA may be inflated by even small increases in the prevalence of smoking relative to the general population. In these cases, an SMR benchmark of 1.0 to represent equal mortality outcomes would be too strict.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
类风湿性关节炎标准化死亡率中与吸烟有关的偏差:模型研究
目标类风湿性关节炎(RA)的标准化死亡率(SMRs)在年龄和性别上与普通人群相匹配,但可能存在偏差,因为吸烟在RA群体中更为常见。这项建模研究使用吸烟者和非吸烟者的全国死亡率数据来估算类风湿性关节炎患者吸烟率通常较高对SMR的影响。方法使用1999-2004年美国全国健康访谈调查的数据创建假定队列,该队列的年龄-性别构成为典型的类风湿性关节炎患者(30-79岁;70%为女性)。参考队列的吸烟率与普通人群相同(21.8% 的当前吸烟者)。与参考队列相比,吸烟相对风险分别为 1.25、1.5、1.75 和 2.0。对 2000 个重复样本计算了 SMRs,比较了吸烟率较高的模拟 RA 队列和参照队列 10 年和 15 年的死亡率。在吸烟率较高的假设 RA 队列中(与普通人群相比,吸烟相对风险为 2.0),10 年和 15 年的 RA SMR 中位数分别为 1.23 和 1.17。在吸烟率相当于相对风险1.25的情况下,RA的中位SMR在10岁时为1.07,15岁时为1.04。根据曾经吸烟者与从不吸烟者的相对风险比较得出的SMR结果类似。假设的RA群体和参考队列之间吸烟强度的差异对SMR的影响较小。在这种情况下,将 SMR 基准定为 1.0 以代表相同的死亡率结果未免过于严格。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.20
自引率
4.00%
发文量
176
审稿时长
46 days
期刊介绍: Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.
期刊最新文献
The overlooked epidemic: Fibromyalgia in the shadows of long COVID. Smoking-related bias of standardized mortality ratios in rheumatoid arthritis: A modeling study The pathogenesis, diagnostic utility and clinical relevance of cutaneous telangiectasia in systemic sclerosis Prediction models for treatment success after an interdisciplinary multimodal pain treatment program Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1